OraSure Technologies, Inc. (NASDAQ: OSUR) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $242M. The Maz Rating grades it against the other companies in its sector.
OraSure Technologies, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.51, OraSure Technologies, Inc. trades at 2.1x sales and 0.8x book value. Over the last twelve months it generated about $115M of revenue and a net loss of $47M. It runs a gross margin of 41.9%, an operating margin of -40.9% and a net margin of -41.7%. It shows return on equity of -15.2%, return on invested capital of -14.6% and a free cash flow yield of -20.5%. On the balance sheet: a debt-to-equity ratio of 0.04 and a current ratio of 8.58. Over the past 52 weeks the share price ranged from $2.08 to $4.58, with a beta of 1.06.
OraSure Technologies, Inc. does not currently pay a dividend.
13 Wall Street analyst ratings cover the stock: 4 Buy and 9 Hold, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, OraSure Technologies, Inc. (OSUR) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 67.1% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 57.9% / 33% · Receivables / Mkt Cap (36m) 12.4% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 57.9% / 33.33% · Receivables / Mkt Cap (24m) 12.4% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 2.01% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 45.9% / 33.33% · Receivables / Avg Assets (4Q) 7.11% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 42.4% / 33.33% · (Cash+Recv) / Total Assets 51.5% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, OraSure Technologies, Inc. (OSUR) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. OraSure Technologies, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
OraSure Technologies, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.